Demand Party: Big pharma in China
Therapeutic Area: Cancer
Indication: Various solid tumors
Target/MOA: HER2
Current Stage: Open
Molecular Entity: Small molecule preferred
Rights: Mainland China right, Greater China Region right, open for discussions
Cooperation Model: Licensing
Special requirement: The product must show good BBB penetration data
Contact info: If interested, please contact DrugTimes BD Team at BD@drugtimes.cn
发布者：DrugTimes001，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 